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Hirullin P18 is a 61-amino acid hirudin-related protein having potent antithrombin activity. Similar to hirudin, it contains a highly acidic C-termi- 
nus, but has a significantly different sequence from any other known hirudin variant. The present study demonstrates that the C-terminal fragment 
acetyl-hirullin Pl8,,,,, p assesses an antithrombin potency similar to that of acetyl-desulfatohirududirL,,,. Additionally, like the hirudin fragment 
analog, it inhibits fibrin-clot formation by binding to a non-catalytic site on thrombin. Sequential shortening of the hirullin P18 C-terminal fragment 
demonstrates the critical nature of PheSi, which corresponds to the important Phd6 residue of hirudin. Although the sequences of hirullin Pl8,,, 
and hirudin,,, have substantial differences, the C-terminal functional domain represented by hirullin Pl8,,,, appears to be comparable to hiru- 
dins,,, in terms of its functional role in antithrombin activity. 
Hirullin P 18; Hirudin; Synthetic peptide; Thrombin 
1. INTRODUCTION 
Hirullin P18 is a 61 amino acid protein isolated from 
the leech, Hirudinaria manillensis, having potent an- 
tithrombin activity (Ki = 7.8 PM) [ 11. Although the pro- 
tein appears to be related to hirudin, based on its se- 
quence, it contains less homology to hirudin (variant 1) 
than any of the other previously reported hirudin 
variants [1,2]. Hirullin P18 contains considerable dif- 
ferences in its C-terminal region, which includes the loss 
of a conserved sulfated tyrosine residue (Fig. 1). These 
differences are significant because the C-terminus of 
hirudin represents a highly conserved domain which 
binds to thrombin at a non-catalytic site [3,4]. This do- 
main accounts for a significant portion of hirudin’s 
overall binding energy to thrombin. Therefore, in order 
to examine the importance of this variant domain and 
compare it to hirudin’s C-terminal functional domain, 
C-terminal fragment peptides of hirullin P18 were syn- 
thesized and studied for their ability to inhibit thrombin 
mediated fibrin-clot in human plasma. The effect of 
these hirullin fragments on thrombin’s ability to cleave 
the small chromogenic substrate S-2238 was also tested 
in order to further confirm that these peptides bind to 
a non-catalytic site on thrombin as do the hirudin C- 
terminal peptides [3,5,6]. 
2. EXPERIMENTAL 
2.1. Peptide synthesis 
Correspondence address: J.L. Krstenansky, Merrell Dow Research 
Institute, 2110 E. Galbraith Road, Cincinnati, Ohio 45215, USA 
Abbreviations: AAA, amino acid analysis; Boc, t-butoxycarbonyl; 
Bzl, benzyl; Chx, cyclohexyl; 2-CIZ, 2-chlorobenzyloxycarbonyl; 
DCC, N,N’-dicyclohexylcarbodiimide; DCM, dichloromethane; 
DMF, N,N-dimethylformamide; FAB-MS, fast-atom bombardment 
mass spectrometry; HOBT, I-hydroxybenzotriazole; HP18, W- 
acetylhirullin P184a_61; HPLC, high performance liquid chromato- 
graphy; Hyp, Chydroxy-L-proline; Pip, L-pipecolic acid; pNA, p- 
nitroanilide; Tos, tosyl 
Peptides were synthesized on a 0.1 mmol scale by solid-phase 
methods starting with 0.5 mmol Boc-Gln-PAM resin (0.64 mmol/g; 
Applied Biosystems, Foster City, CA) using an Applied Biosystems 
model 430-A peptide synthesizer. As the synthesis proceeded, approx- 
imately 0.1 mmol theory of resin was removed at the appropriate 
points to yield the peptide fragment analogs 1-5. All N”-Boc pro- 
tected amino acids were double coupled as their symmetrical 
anhydrides, first in dimethylformamide (DMF) then in 
dichloromethane (DCM), using protocols supplied by the manufac- 
turer. Arginine and glutamine were coupled using N,N’-dicyclohexyl- 
carbodiimide (DCC) and I-hydroxybenzotriazole (HOBT). The side 
chain protection was as follows: Arg(Tos), Asp(Chx). Glu(Bzl), 
Lys(2-ClZ), Ser(Bz1) and Thr(Bz1). The peptides (0.1 mmol, theory) 
were cleaved from the resin support and deprotected in liquid HF con- 
taining 5% anisole at - 5°C for 40 min. After removal of the HF in 
vacua the peptide was extracted from the resin with 30% aqueous 
acetic acid then 25% aqueous acetonitrile. Purification was perform- 
ed by preparative HPLC on a Dynamax Cis column (41.4 x 250 mm: 
Rainin Instruments) using acetonitrile in 0.1% aqueous trifluoro- 
acetic acid as the eluant. The purity and identity of the peptides was 
assessed by analytical PHLC, amino acid analysis @AA) and fast- 
atom bombardment mass spectrometry (FAB-MS). 
2.2. Fibrin-clot inhibition 
The assay was performed in a manner similar to that previously 
described [3,5,6]. The assay buffer (pH 7.4) from which all solutions 
were made consists of 0.12 M sodium chloride, 0.01 M sodium 
phosphate, 0.01% sodium azide and 0.1% bovine serum albumin. 
Bovine thrombin (Sigma, St. Louis, MO) was titrated to a concentra- 
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1 11 
Hirullin P18 8-Val-Ser-Tyr-Thr-Asp-ws-Thr- -Ser-Gly-Gln-Asn- 
Hirudin var. 1 E-Val-Val-Tyr-Thr-Asp-~s-Thr-Glu-Ser-Gly-Gln-Asn- 
1 12 
12 20 28 
Tyr-Cys-Lw-Cys-Gly-Gly- -Asn-Phe-Cys-Gly-Asp-Gly-Lys-llis-Cys-Glu-~et- 
Leu-Cys-Leu-Cys-Glu-Gly-Ser-~n-Val-Cys-Gly-Gln-Gly-Asn-Lys-Cys-Ile-Leu- 
13 20 30 
29 40 43 
Asp-Ser- -Glu-Asn-Lys- - Xys-Val-Asp-Gly-Glu-Gly-Thr-Pro-Lys-Arg- 
Gly-Ser-Asp-Gly-Glu-Lys-Asn-Gln-Cys-Val-Thr-Gly-Glu-Gly-~r-Pro-Lys-Pro- 
31 40 45 48 
44 51 61 
Gln-Thr-Ser-Gly-Pro-Ser-Asp-We-Glu-Glu-Phe-Ser-Leu-Asp-Asp-Ile-Glu-Gln-OE 
Gln-Ser-His-Asn-Asp-Gly-kirp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu- -Gin-08 
49 56 65 
Fig. 1. Sequences of hirullin Pl8 and hirudin [l]. Homologous regions are highlighted by boldface print. 
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tion so that fibrin clot formation could be monitored by a microtiter 
plate reader (Bio-Tek EL 309) within 60 min at 380 nm. This thrombin 
solution (50 d) was added to the wells of a %-well microtiter plate 
containing 50 d of a solution of the peptide being tested. After 1 min 
agitation and an additional 10 min incubation at 24”C, 100 d of 
diluted human plasma (1: 10) in 0.1% EDTA were added and agitated 
for 20 s. The turbidity of the solutions in the wells was monitored by 
the reader at 5 min intervals. The It& was calculated as the concen- 
tration of peptide which led to half of the turbidity observed in a con- 
trol sample containing no inhibitory peptides. 
2.3. S-2238 cleavage 
The ability of human a-thrombin (the kind gift of Dr. John W. 
Fenton II, New York State Department of Health, Albany, New 
York) to cleave the tripeptide chromogenic substrate S-2238 (H-D- 
Phe-Pip-Arg-pNA) was examined in the presence and absence of both 
N”-acetylhirullin P&I -6, (1) and hirudin from leeches (Sigma, St. 
Louis, MO). The stock solutions were as follows: thrombin, 0.0276 
mg/ml in 10 mM Tris buffer pH 8; S-2238, 2 mM in water; 
acetylhirullin Pl&_ sl, 1.95 mM in 1OmM Tris buffer pH 8; himdin, 
5 ATU/ml 10 mM Tris buffer pH 8. The assays were carried out in 
1 cm3 cuvettes using a Beckman DU-7 spectrophotometer monitoring 
absorbance at 405 mn at 20 s intervals. The samples were prepared by 
adding 25 $ of the S-2238 solution to the cuvettes followed by the ap- 
propriate amounts of the hirullin and/or hirudin solutions and buffer 
to bring the total volume at this point to 490 4. The samples were mix- 
e-d and the spectrophotometer calibrated using these solutions. The 
thrombin solutin (10 A) was then added, the cuvettes mixed and the 
absorbance at 405 nm was monitored for 20 min. The results of these 
experiments are in Figs 2 and 3. 
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3. RESULTS AND DISCUSSION 
W-Acetyl-hirulhn P&l-62, 1 had an ICSO for the in- 
hibition of thrombin-induced fibrin-clot formation of 3 
pM, which is virtually the same as that of W-acetyl- 
desulfatohirudir&+65, 6 [3]. Progressive truncation of 
the hirullin peptide, as exemplified by compounds 2-5, 
resulted in a gradual loss of potency until Phe” had 
been removed, which yielded an very weakly active pep- 
tide. This is directly comparable to what is seen with the 
C-terminus of hirudin, compounds 7-10, where the 
removal of Phes6 results in the loss of antithrombin ac- 
tivity [5]. Phes6 of hirudin binds into a lipophilic pocket 
on the surface of thrombin and is involved in an interac- 
tion with Phe34 of thrombin [4]. Phe” of hirullin P18 
may interact with thrombin in a similar fashion par- 
ticularly since it is flanked by Asp and Glu residues 
which are also involved in specific thrombin interac- 
tions in the hirudin-thrombin complex [4]. 
Like the hirudin C-terminal fragment peptides 
[3,5&l, hirullin Pl&O-61 does not block thrombin’s 
ability to cleave the small chromogenic substrate S-2238 
demonstrating that it also blocks fibrin-clot formation 
by binding to a non-catalytic site on thrombin (Fig. 2). 
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Fig. 2. The cleavage of S-2238 by human u-thrombin alone (control) and in the presence of 1,10 and 100 @I W-acetyl-hirullin Pl&_~l (1; HPIB). 
There is no inhibition of S-2238 cleavage at concentrations of HP18 that can inhibit fibrin-clot formation (Table I) and hirudin’s ability to block 
S-2238 cleavage by thrombin. 
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Fig. 3. The effect of I, 10, 100 and 500 #I W-acdyl-hi&in P&J_s~ (1; HP18) on the ability of hirudin (Hirudin alone) to block the cleavage 
of S-2238 by human a-thrombin (control = no hirudin or HPl8). HP18 can block hirudin binding to thrombin but does not block S-2238 cleavage 
and thereby prevents hiidin’s blockade of S-2238 cleavage by thrombin. 
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Also the hirullin P18 peptide can block hirudin’s ability 
to inhibit thrombin-induced S-2238 cleavage (Fig. 3) as 
has been demonstrated for the hirudin peptides [6]. The 
experiment, whose results are depicted in Fig. 3, was 
constructed in the following way. Human cy-thrombin 
was added to a cuvette containing S-2238, hirudin and 
N*-acetyl-hirullin P 1840-61. The subsequent cleavage of 
S-2238 by the thrombin was followed by measuring the 
absorbance at 405 nm. With no hirudin or hirullin P18 
peptide present the S-2238 was cleaved within 4 min 
(open boxes). A concentration of hirudin was chosen 
which, in the absence of the hirullin P18 peptide, gave 
a nearly total blockade of the S-2238 cleavage (filled 
boxes). The hirullin P18 peptide was able to compete in 
a dose-dependent fashion with hirudin for binding to 
thrombin as evidenced by the level of S-2238 cleavage 
permitted by the hirullin P18 peptide-protected throm- 
bin. Over time hirudin was eventually able to fully oc- 
cupy the thrombin present as the thrombin-hirullin P18 
peptide complex in solution dissociated, This occurs 
because of hirudin’s extremely tight, but non-covalent, 
binding to thrombin which results in a virtually irrever- 
sible complex. Therefore, eventually, the hirudin- 
thrombin complex dominates and the S-2238 cleavage 
rate reflects this event. This can be seen most clearly 
from the 10 and 100 ,uM hirullin P18 peptide curves of 
Fig. 3, where the initial rates of S-2238 cleavage are not 
much different from the ‘no hirudin’ control sample, 
but over time the rate slows to that of the ‘hirudin 
alone’ control. 
While it is likely that hirullin P1850-61 and 
hirudinss-6s bind to the same site on thrombin, the 
54-59 region of hirullin P18, which corresponds to 
hirudin+u, should bind to thrombin in a different 
conformation. The ability of these hirullin P18 
fragments to bind to thrombin is not readily explained 
by the structure activity relationships of the comparable 
hirudin peptides [6]. There are three notable differences 
between hirullin P18 and hirudin in this domain which 
support differing modes of interaction: (i) Prom of 
hirudin is replaced by Ser”. In hirudin this residue 
plays a critical conformational role [6] and in the crystal 
structure of the hirudin-thrombin complex, it is in a 
lipophilic environment packed against Tyr76 and Ile*’ 
[4]. Replacement by Ser would not be predicted by the 
structure-activity studies of hirudin C-terminal peptides 
to be favorable for thrombin interaction even though 
4-hydroxy-proline is an acceptable Pro substitution [6]. 
NMR studies of the complex between hirudin C- 
terminal peptide fragments and thrombin demonstrate 
that the Pro@’ side chain resides on the lipophilic face of 
an amphipathic structure in close proximity to the side 
chains of Iles9 and Tyr63 as evidenced by the observa- 
tion of transfer NOES [7]. With no alteration of confor- 
mation, Ser at this position results in the unfavorable 
placement of a hydrophilic group on the lipophilic face. 
(ii) There is no Tyr residue in hirullin P18 for sulfation, 
which although not necessary for activity, can con- 
tribute a significant amount to the potency. In view of 
the thrombin-bound hirudin conformation [4], the 
Asp5* residue of hirullin P18 would not be of sufficient 
length to interact with the basic thrombin residues 
which have been proposed to interact with a hirudin 
sulfated Tyr residue. (iii) The lipophilic side chains 
Ile59, Prom and Let?’ of hirudin pack neatly in a 
lipophilic cleft on thrombin’s surface [4]. Phe54, Leu56 
and Iles9 of hirullin P18 would require a significantly 
different backbone conformation in order to pack these 
lipophilic residues into the same cleft. If this region of 
hirullin P18 bound in the same conformation as 
hirudin, the LeuS6 residue would be fully exposed to 
aqueous phase as is G1u6r of hirudin. Again the NMR 
studies of the complex of hirudin C-terminal fragment 
peptides and thrombin emphasize the prominent 
feature of an amphipathic structure [7]. Such an ar- 
rangement is favorable for macromolecular interaction 
since it allows for optimum removal of the lipophilic 
residues from the aqueous solution upon their interac- 
tion with the binding site. Hirullin P18’s C-terminal 
region would require a different backbone conforma- 
tion to remove Leu’6 from the polar face yielding a fully 
amphipathic structure. (iv) It can also be noted that 
Table 1 
Inhibition of thrombin-induced fibrin-clot formation by synthetic peptides 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Sequence Compound 
AC-TPKRQTSGPSDFEEFSLDDIEQ Ac-hirullin P1840-61 
SDFEEFSLDDIEQ hirullin Pl849-6r 
DFEEFSLDDIEQ hirullin P18se_6r 
FEEFSLDDIEQ hirullin P18sr_sr 
EEFSLDDIEQ hirullin P&r_sr 
AC-TPKPQSHNDGDFEEIPEEYLQ AC-hirudilLs_65 
GDFFEIPEEYLQ hirudins4-6s 
DFEEIPEEYLQ hirudin~s-65 
FEEIPEEYLQ hirudin+es 
EEIPEEYLQ hirudinsr-6s 
Standard one-letter code is used for the amino acid sequences; AC, acetyl. 
lClr0 
WW 
2.7 
4.2 
9.3 
23 
410 
1.6 
3.7 
7.1 
34 
> 270 
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acetylhirullin P1840-61 does not appear to cause the 
slight acceleration of S-2238 cleavage by thrombin that 
is seen with the hirudin peptides (Fig. 2) [6]. This might 
suggest some subtle differences in their modes of in- 
teraction with thrombin. 
In conclusion, hirullin P18 represents a unique 
variant of hirudin which has a significantly different C- 
terminal functional domain that binds thrombin with 
similar affinity to that of hirudin’s C-terminal func- 
tional domain. Similarities in a portion of the domain, 
a comparable potency profile for the peptide frag- 
ments, the inability to block thrombin-induced S-2238 
cleavage, and the ability to inhibit hirudin blockade of 
S-2238 cleavage by thrombin all suggest hat despite dif- 
ferences, which would necessitate adifferent conforma- 
tional mode of binding, this domain probably binds the 
same site on thrombin as hirudinss-6s. Physical studies 
are underway to further characterize the interaction of 
hirullin P18’s C-terminal domain with thrombin. 
Hirullin P18 represents a new approach for the ex- 
amination of thrombin’s selectity for ligands and offers 
potential therapeutic agents based on the protein or its 
functional domains. 
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